CDK-IN-13

• UNSPSC Description:

  CDK-IN-13 (compound 32E) is a potent and selective inhibitor of CDK12/cyclinK with an IC50 of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk-in-13.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCN1C=NC2=C(N=C(N=C21)N3CCOC[C@H]3CCO)NCC4=CN=C(C=C4)C5=COC=C5

• Molecular Weight:

  449.51

• References & Citations:

  [1]Kuchukulla RR, et al. Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo. Eur J Med Chem. 2024 Jan 15;264:116014.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported